<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756544</url>
  </required_header>
  <id_info>
    <org_study_id>RNN/228/20/KE</org_study_id>
    <nct_id>NCT04756544</nct_id>
  </id_info>
  <brief_title>The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity</brief_title>
  <acronym>PRO-DEMET</acronym>
  <official_title>he Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lodz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will be a four-arm, parallel group, prospective, randomized, double-blind,&#xD;
      controlled design that will include 200 participants and will last 20 weeks. The probiotic&#xD;
      preparation will contain Lactobacillus helveticus Rosell®-52, Bifidobacterium longum&#xD;
      Rosell®-175. We will assess the level of depression, anxiety and stress, quality of life,&#xD;
      blood pressure, body mass index and waist circumference, white blood cells count, serum&#xD;
      levels of C-reactive protein, HDL cholesterol, triglicerides, fasting glucose, faecal&#xD;
      microbiota composition and the level of some faecal microbiota metabolites, as well as&#xD;
      inflammation markers and oxidative stress parameters in serum.&#xD;
&#xD;
      The trial may establish a safe and easy-to-use treatment option as an adjunct in a&#xD;
      subpopulation of depressive patients only partially responsive to pharmacologic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>depressive symptoms</measure>
    <time_frame>2 years</time_frame>
    <description>MADRS score</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Stress</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Depressive Disorders + probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Depressive Disorders + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Depressive disorder + metabolic syndrome + probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Depressive disorder + metabolic syndrome + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175</intervention_name>
    <description>probiotic</description>
    <arm_group_label>Depressive Disorders + probiotic</arm_group_label>
    <arm_group_label>Depressive disorder + metabolic syndrome + probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Depressive Disorders + placebo</arm_group_label>
    <arm_group_label>Depressive disorder + metabolic syndrome + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Depressive disorders diagnosed according to ICD Age between 18 and 70 years MADRS score&#xD;
        &gt;=13 Antidepressant and antianxiety medications or psychotherapy not changed 3 weeks prior&#xD;
        to the beginning of the study DMS study groups: MetS diagnosed according to International&#xD;
        Diabetes Federation (IDF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnancy; An infection and/or treatment with antibiotics in the previous 4 weeks;&#xD;
        Supplementation with pro- or prebiotics in the previous 4 weeks; Having a diagnosis of&#xD;
        autoimmune, serious immunocompromised, inflammatory bowel diseases, cancer, IgE-dependent&#xD;
        allergy, severe kidney failure or unstable thyroid dysfunction in the previous 4 weeks;&#xD;
        Psychiatric comorbidities (except for specific personality disorder, additional specific&#xD;
        anxiety disorder and caffeine or nicotine addiction); Regular treatment (more than 3 days a&#xD;
        week) with proton-pump inhibitors (PPIs), metformin, laxatives, systemic steroids or&#xD;
        nonsteroidal anti-inflammatory drugs (NSAIDs) in the previous 4 weeks; Following a specific&#xD;
        diet or a significant change in dietary pattern in the previous 4 weeks; Significant change&#xD;
        in daily physical activity or an extreme sport activity in the previous 4 weeks;&#xD;
        Significant change in dietary supplementation in the previous 4 weeks; Significant change&#xD;
        in smoking pattern in the previous 4 weeks; A major neurological disorder or any medical&#xD;
        disability that may interfere with a subject's ability to complete study procedures; High&#xD;
        risk of suicide according to Tool of Assessment of Suicide Risk (TASR); Is participating&#xD;
        in, or has recently participated in, another research study involving an intervention which&#xD;
        may alter outcomes of interest to this study; Any other condition or situation which, in&#xD;
        the view of investigators, would affect the compliance or safety of the individual taking&#xD;
        part; D study groups: MetS diagnosed according to International Diabetes Federation (IDF).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oliwia Gawlik-kotelnicka</last_name>
    <phone>+48426757236</phone>
    <email>oliwia.gawlik@umed.lodz.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oliwia Gawlik-Kotelnicka</name>
      <address>
        <city>Łódź</city>
        <zip>92216</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliwia Gawlik-kotelnicka</last_name>
      <phone>+48426757236</phone>
      <email>oliwia.gawlik@umed.lodz.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lodz</investigator_affiliation>
    <investigator_full_name>Oliwia Gawlik-Kotelnicka, MD, PhD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>depression; metabolic syndrome; probiotics; microbiota; inflammation; oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

